Home

ROBERT R RUFFOLO

CIK 1187308 · Sr. VP & Pres., Wyeth Research · last filed 2026-09-02

ROBERT R RUFFOLO is a Sr. VP & Pres., Wyeth Research who has filed 24 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ELTX, was dated Sep 2, 2026. Across all open-market trades the lifetime net is −$7.7M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

6

Total Filings

24

Lifetime Open-Market Net

-$7.68M

Filer Profile

Reported Address
WYETH
FIVE GIRALDA FARMS
MADISON, NJ 07940
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ELTX Director — $2.41 — $0 4 2026-09-02
LBRX Director — $49.34 — $0 2 2026-06-05
Sigilon Therapeutics, Inc. (SGTX) Delisted Director 519 $22.47 $11.7K -$69.9K 6 2023-08-11
Aridis Pharmaceuticals, Inc. (ARDS) Delisted Director — $0.31 — $0 3 2022-12-07
CervoMed Inc. (DFFN) Delisted Director — $6.60 — $0 3 2018-06-18
WYETH (WYE) Delisted Sr. VP & Pres., Wyeth Research 293,256 — — -$7.61M 6 2008-03-04

Recent Filings

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 ELTX Grant (A) — $0 EDGAR
2026-06-05 LBRX Grant (A) — $0 EDGAR
2025-09-12 LBRX Mixed — $0 EDGAR
2025-05-20 ELTX Grant (A) — $0 EDGAR
2024-11-25 ELTX Grant (A) — $0 EDGAR
2023-12-29 ELTX Grant (A) — $0 EDGAR
2023-08-11 Sigilon Therapeutics, Inc. (SGTX) Delisted Disp (D) — $0 EDGAR
2023-05-22 Sigilon Therapeutics, Inc. (SGTX) Delisted Grant (A) — $0 EDGAR
2022-12-07 Aridis Pharmaceuticals, Inc. (ARDS) Delisted Grant (A) — $0 EDGAR
2022-05-27 Sigilon Therapeutics, Inc. (SGTX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 24
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.